-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DNTH-103 in Multifocal Motor Neuropathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DNTH-103 in Multifocal Motor Neuropathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DNTH-103 in Multifocal Motor Neuropathy Drug Details: DNTH-103 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DNTH-103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DNTH-103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DNTH-103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug...
-
Product Insights
NewMultifocal Motor Neuropathy – Drugs In Development, 2024
Empower your strategies with our Multifocal Motor Neuropathy – Drugs In Development, 2024 report and make more profitable business decisions. Multifocal motor neuropathy (MMN), or multifocal motor neuropathy with conduction block (MMNCB), is a rare acquired motor neuropathy characterized by progressive asymmetric weakness without sensory problems. Symptoms include weakness in the hands and lower arms, cramping, involuntary contractions or twitching, wrist drop, or foot drop. Nerve conduction studies can be used for diagnosis. The main pharmacological treatment option for MMN is...
-
Product Insights
NewChronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Drugs In Development, 2024
Empower your strategies with our Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Drugs In Development, 2024 report and make more profitable business decisions. Chronic inflammatory demyelinating polyneuropathy (CIDP), also called as chronic relapsing polyneuropathy, is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disease is caused by damage to the myelin sheath of the peripheral nerves. Symptoms include initial limb weakness, both proximal and distal; orthostatic dizziness; and tingling and numbness of hands...
-
Product Insights
NewPeripheral Neuropathy (Sensory Neuropathy) – Drugs In Development, 2024
Empower your strategies with our Peripheral Neuropathy (Sensory Neuropathy) – Drugs In Development, 2024 report and make more profitable business decisions. Peripheral neuropathy refers to a condition that involves damage or dysfunction of the peripheral nerves, resulting in various sensory, motor, and autonomic symptoms. These nerves transmit signals between the central nervous system (brain and spinal cord) and the rest of the body, controlling muscle movements, sensation, and organ function. There are different types of peripheral neuropathy, each affecting specific nerves...
-
Product Insights
NewMyasthenia Gravis – Drugs In Development, 2024
Empower your strategies with our Myasthenia Gravis – Drugs In Development, 2024 report and make more profitable business decisions. Myasthenia gravis is an autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia, and difficulty swallowing, chewing, and speaking. Treatment includes immunosuppressants, corticosteroids, and surgery. The Myasthenia Gravis drugs in development market research report provide comprehensive information on the therapeutics under development for Myasthenia Gravis,...
-
Product Insights
NewNeuropathy – Drugs In Development, 2024
Empower your strategies with our Neuropathy – Drugs In Development, 2024 report and make more profitable business decisions. Neuropathy, also known as peripheral neuropathy, refers to a condition involving damage or dysfunction of the nerves outside the brain and spinal cord (peripheral nerves). This condition can affect a single nerve or multiple nerves and can result from various causes. Common types include diabetic neuropathy, resulting from diabetes-related nerve damage due to high blood sugar levels; peripheral neuropathy, often due to conditions...
-
Product Insights
NewAcquired (Autoimmune) Hemolytic Anemia – Drugs In Development, 2024
Empower your strategies with our Acquired (Autoimmune) Hemolytic Anemia – Drugs In Development, 2024 report and make more profitable business decisions. Acquired autoimmune hemolytic anemia (AIHA) is a rare blood disorder characterized by the immune system mistakenly attacking and destroying red blood cells. Red blood cells carry oxygen throughout the body, and their destruction leads to anemia (low red blood cell count), causing fatigue, pale skin, and other symptoms. AIHA can be classified into "warm" and "cold" types, depending on the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INNA-051 in Influenza A Virus, H3N2 Subtype Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.INNA-051 in Influenza A Virus, H3N2 Subtype Infections Drug Details: INNA-051 (INNA-X) is under development for...